PL3607939T3 - Formulacje farmaceutyczne zawierające tenofowir i emtrycytabinę - Google Patents
Formulacje farmaceutyczne zawierające tenofowir i emtrycytabinęInfo
- Publication number
- PL3607939T3 PL3607939T3 PL19199257.7T PL19199257T PL3607939T3 PL 3607939 T3 PL3607939 T3 PL 3607939T3 PL 19199257 T PL19199257 T PL 19199257T PL 3607939 T3 PL3607939 T3 PL 3607939T3
- Authority
- PL
- Poland
- Prior art keywords
- emtricitabine
- tenofovir
- pharmaceutical formulations
- formulations
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562187113P | 2015-06-30 | 2015-06-30 | |
| US201662298373P | 2016-02-22 | 2016-02-22 | |
| US201662301429P | 2016-02-29 | 2016-02-29 | |
| US201662317286P | 2016-04-01 | 2016-04-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3607939T3 true PL3607939T3 (pl) | 2022-11-07 |
Family
ID=56418608
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19199257.7T PL3607939T3 (pl) | 2015-06-30 | 2016-06-29 | Formulacje farmaceutyczne zawierające tenofowir i emtrycytabinę |
| PL23162978.3T PL4233846T3 (pl) | 2015-06-30 | 2016-06-29 | Formulacje farmaceutyczne |
| PL22176537.3T PL4070788T3 (pl) | 2015-06-30 | 2016-06-29 | Formulacje farmaceutyczne |
| PL16739625T PL3316868T3 (pl) | 2015-06-30 | 2016-06-29 | Formulacje farmaceutyczne zawierające tenofowir i emtrycytabinę |
| PL22176524.1T PL4070787T3 (pl) | 2015-06-30 | 2016-06-29 | Formulacje farmaceutyczne |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL23162978.3T PL4233846T3 (pl) | 2015-06-30 | 2016-06-29 | Formulacje farmaceutyczne |
| PL22176537.3T PL4070788T3 (pl) | 2015-06-30 | 2016-06-29 | Formulacje farmaceutyczne |
| PL16739625T PL3316868T3 (pl) | 2015-06-30 | 2016-06-29 | Formulacje farmaceutyczne zawierające tenofowir i emtrycytabinę |
| PL22176524.1T PL4070787T3 (pl) | 2015-06-30 | 2016-06-29 | Formulacje farmaceutyczne |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US20170000807A1 (pl) |
| EP (6) | EP4070787B1 (pl) |
| JP (3) | JP6667556B2 (pl) |
| KR (2) | KR102313668B1 (pl) |
| CN (2) | CN107847450A (pl) |
| AU (3) | AU2016287500B2 (pl) |
| BR (1) | BR112017027843A2 (pl) |
| CA (1) | CA2990210C (pl) |
| CL (1) | CL2017003320A1 (pl) |
| CO (1) | CO2017013293A2 (pl) |
| CU (1) | CU20170168A7 (pl) |
| DO (1) | DOP2017000306A (pl) |
| EA (1) | EA201792592A1 (pl) |
| EC (1) | ECSP17084331A (pl) |
| ES (5) | ES2786549T3 (pl) |
| HK (1) | HK1248547A1 (pl) |
| IL (1) | IL256364A (pl) |
| MA (1) | MA50541A (pl) |
| MX (1) | MX2017016806A (pl) |
| PE (1) | PE20180411A1 (pl) |
| PH (1) | PH12017502431A1 (pl) |
| PL (5) | PL3607939T3 (pl) |
| PT (4) | PT3607939T (pl) |
| SI (4) | SI3607939T1 (pl) |
| SV (1) | SV2017005601A (pl) |
| WO (1) | WO2017004244A1 (pl) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013361401C1 (en) | 2012-12-21 | 2018-08-09 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
| SMT202100592T1 (it) | 2014-12-26 | 2021-11-12 | Univ Emory | Derivati antivirali della n4-idrossicitidina |
| NZ741957A (en) | 2015-11-09 | 2019-04-26 | Gilead Sciences Inc | Therapeutic compositions for treatment of human immunodeficiency virus |
| WO2018151815A1 (en) | 2017-02-17 | 2018-08-23 | Eidos Therapeutics, Inc. | Processes for preparing ag-10, its intermediates, and salts thereof |
| WO2018153977A1 (en) * | 2017-02-24 | 2018-08-30 | Hexal Ag | Stable composition of tenofovir alafenamide |
| WO2018175325A1 (en) * | 2017-03-20 | 2018-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hiv post-exposure prophylaxis |
| RU2662160C9 (ru) * | 2017-07-03 | 2018-10-22 | Александрович Иващенко Андрей | Комбинированный лекарственный препарат для терапии вирусных инфекций |
| KR20240011880A (ko) | 2017-12-07 | 2024-01-26 | 에모리 유니버시티 | N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도 |
| KR20200135996A (ko) | 2018-03-23 | 2020-12-04 | 에이도스 테라퓨틱스, 인코포레이티드 | Ag10을 사용하여 ttr 아밀로이드증을 치료하는 방법 |
| SMT202500463T1 (it) | 2018-08-17 | 2026-01-12 | Eidos Therapeutics Inc | Formulazioni di ag10 |
| CN111096954B (zh) * | 2018-10-29 | 2022-09-16 | 江苏豪森药业集团有限公司 | 一种用于抗病毒感染的药物组合物及制备方法 |
| AU2020300818A1 (en) * | 2019-07-03 | 2022-03-03 | Janssen Sciences Ireland Unlimited Company | Methods of treating HIV in pediatric patients with rilpivirine |
| CN110251476B (zh) * | 2019-08-01 | 2022-08-09 | 海思科制药(眉山)有限公司 | 一种恩曲他滨替诺福韦药物组合物 |
| CN110917197A (zh) * | 2019-12-31 | 2020-03-27 | 常州恒邦药业有限公司 | 一种替诺福韦酯与恩曲他滨的药物组合物及其制备方法 |
| TWI728709B (zh) * | 2020-02-19 | 2021-05-21 | 台灣森本生物科技開發股份有限公司 | 含有得自於藤黃樹脂的丙酮萃取產物的藥學組成物以及由該組成物所製得的配方 |
| WO2024211882A1 (en) * | 2023-04-07 | 2024-10-10 | Navinta, Llc | Stable compositions of rilpivirine hcl in combination with other anti-retroviral agents |
| CN117338733B (zh) * | 2023-10-12 | 2024-05-28 | 杭州和泽坤元药业有限公司 | 一种富马酸替诺福韦二吡呋酯片及其制备工艺 |
| WO2025229473A1 (en) * | 2024-05-01 | 2025-11-06 | Lupin Limited | Tenofovir alafenamide compositions |
| CN119174735A (zh) * | 2024-09-03 | 2024-12-24 | 安徽贝克生物制药有限公司 | 一种含利匹韦林的复方片及制备方法 |
| CN119139247A (zh) * | 2024-09-05 | 2024-12-17 | 安徽贝克生物制药有限公司 | 一种恩曲他滨丙酚替诺福韦复方片及制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ304886B6 (cs) | 2000-07-21 | 2015-01-07 | Gilead Sciences, Inc. | Prekurzory léčiv na bázi fosfonátových analogů nukleotidů a způsoby jejich výběru a přípravy |
| JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| AP2089A (en) * | 2003-01-14 | 2010-01-11 | Gilead Sciences Inc | Compositions and methods for combination antiviraltherapy |
| TWI471145B (zh) * | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
| HRP20151009T1 (hr) | 2009-02-06 | 2015-10-23 | Gilead Sciences, Inc. | Dvoslojna tableta koja sadrži elvitegravir, kobicistat, emtricitabin i tenofovir |
| SMT201600476T1 (it) | 2011-08-16 | 2017-03-08 | Gilead Sciences Inc | Tenofovir alafenammide emifumarato |
| JP6059255B2 (ja) * | 2012-02-03 | 2017-01-11 | ギリアード サイエンシス インコーポレーテッド | ウイルス感染の処置における使用のためのテノホビルアラフェンアミドヘミフマル酸塩とコビシスタットを含む併用療法 |
| US20160184332A1 (en) * | 2013-08-14 | 2016-06-30 | Ratiopharm Gmbh | Medicament comprising a pharmaceutical combination of drugs |
| CZ2013985A3 (cs) * | 2013-12-09 | 2015-06-17 | Zentiva, K.S. | Stabilní farmaceutická kompozice obsahující tenofovir disoproxil fumarát |
| NO2717902T3 (pl) * | 2014-06-20 | 2018-06-23 |
-
2016
- 2016-06-29 PL PL19199257.7T patent/PL3607939T3/pl unknown
- 2016-06-29 SI SI201631582T patent/SI3607939T1/sl unknown
- 2016-06-29 MX MX2017016806A patent/MX2017016806A/es unknown
- 2016-06-29 ES ES16739625T patent/ES2786549T3/es active Active
- 2016-06-29 EP EP22176524.1A patent/EP4070787B1/en active Active
- 2016-06-29 US US15/197,491 patent/US20170000807A1/en not_active Abandoned
- 2016-06-29 CA CA2990210A patent/CA2990210C/en active Active
- 2016-06-29 CN CN201680045136.1A patent/CN107847450A/zh active Pending
- 2016-06-29 PT PT191992577T patent/PT3607939T/pt unknown
- 2016-06-29 SI SI201631707T patent/SI4070787T1/sl unknown
- 2016-06-29 EP EP22176537.3A patent/EP4070788B1/en active Active
- 2016-06-29 SI SI201630656T patent/SI3316868T1/sl unknown
- 2016-06-29 EP EP19199257.7A patent/EP3607939B1/en active Active
- 2016-06-29 PE PE2017002785A patent/PE20180411A1/es unknown
- 2016-06-29 PT PT221765373T patent/PT4070788T/pt unknown
- 2016-06-29 ES ES19199257T patent/ES2925246T3/es active Active
- 2016-06-29 PL PL23162978.3T patent/PL4233846T3/pl unknown
- 2016-06-29 ES ES22176524T patent/ES2945345T3/es active Active
- 2016-06-29 CN CN202411894523.5A patent/CN119606990A/zh active Pending
- 2016-06-29 EP EP24216441.6A patent/EP4527467A3/en active Pending
- 2016-06-29 PL PL22176537.3T patent/PL4070788T3/pl unknown
- 2016-06-29 EA EA201792592A patent/EA201792592A1/ru unknown
- 2016-06-29 PT PT167396258T patent/PT3316868T/pt unknown
- 2016-06-29 EP EP23162978.3A patent/EP4233846B1/en active Active
- 2016-06-29 HK HK18108248.3A patent/HK1248547A1/zh unknown
- 2016-06-29 KR KR1020207016036A patent/KR102313668B1/ko active Active
- 2016-06-29 SI SI201631702T patent/SI4070788T1/sl unknown
- 2016-06-29 AU AU2016287500A patent/AU2016287500B2/en active Active
- 2016-06-29 KR KR1020187002382A patent/KR102121329B1/ko active Active
- 2016-06-29 PL PL16739625T patent/PL3316868T3/pl unknown
- 2016-06-29 ES ES22176537T patent/ES2945896T3/es active Active
- 2016-06-29 EP EP16739625.8A patent/EP3316868B1/en active Active
- 2016-06-29 PL PL22176524.1T patent/PL4070787T3/pl unknown
- 2016-06-29 JP JP2017566409A patent/JP6667556B2/ja active Active
- 2016-06-29 MA MA050541A patent/MA50541A/fr unknown
- 2016-06-29 BR BR112017027843-0A patent/BR112017027843A2/pt not_active Application Discontinuation
- 2016-06-29 CU CUP2017000168A patent/CU20170168A7/xx unknown
- 2016-06-29 US US15/738,067 patent/US20180177734A1/en not_active Abandoned
- 2016-06-29 ES ES23162978T patent/ES3007987T3/es active Active
- 2016-06-29 PT PT221765241T patent/PT4070787T/pt unknown
- 2016-06-29 WO PCT/US2016/040158 patent/WO2017004244A1/en not_active Ceased
-
2017
- 2017-12-17 IL IL256364A patent/IL256364A/en unknown
- 2017-12-21 SV SV2017005601A patent/SV2017005601A/es unknown
- 2017-12-21 EC ECIEPI201784331A patent/ECSP17084331A/es unknown
- 2017-12-21 DO DO2017000306A patent/DOP2017000306A/es unknown
- 2017-12-21 CO CONC2017/0013293A patent/CO2017013293A2/es unknown
- 2017-12-21 CL CL2017003320A patent/CL2017003320A1/es unknown
- 2017-12-22 PH PH12017502431A patent/PH12017502431A1/en unknown
-
2019
- 2019-07-31 AU AU2019210558A patent/AU2019210558B2/en active Active
-
2020
- 2020-02-25 JP JP2020029330A patent/JP6978534B2/ja active Active
-
2021
- 2021-03-31 AU AU2021202009A patent/AU2021202009B2/en active Active
- 2021-09-01 JP JP2021142184A patent/JP2021185188A/ja active Pending
-
2025
- 2025-02-07 US US19/048,549 patent/US20250281412A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL256364A (en) | Pharmaceutical formulations containing tenofovir and emtricitabine | |
| GB201620066D0 (en) | Solid Pharmaceutical dosage formulations and processes | |
| ZA201903101B (en) | Pharmaceutical formulations | |
| IL256491A (en) | Pharmaceutical formulations | |
| IL271226A (en) | medical preparation | |
| PT3380525T (pt) | Formulações farmacêuticas e métodos que as utilizam | |
| IL248095A0 (en) | Dosage unit containing emtricitabine, tenofovir, dronavir and ritonavir | |
| IL262745A (en) | Improved preparations containing drugs | |
| ZA201707094B (en) | Pharmaceutical formulations | |
| PT3326619T (pt) | Composições farmacêuticas orais sólidas compreendendo tenofovir e emtricitabina | |
| PT3302483T (pt) | Composições farmacêuticas e seu uso | |
| SI3601277T1 (sl) | Farmacevtska formulacija | |
| EP3497080A4 (en) | PHARMACEUTICAL FORMULATIONS AND THEIR USE | |
| IL275144A (en) | Pharmacy preparation | |
| IL271908A (en) | Over-compressed pharmaceutical preparations | |
| HUE053181T2 (hu) | Gyógyszerészeti készítmény megnövelt oldékonysággal és stabilitással | |
| GB201719873D0 (en) | Pharmaceutical formulation | |
| GB201610440D0 (en) | Pharmaceutical formulations |